Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate dose comparison to suppress anti-TNF immunogenicity in IBD with loss of response
NL-OMON48064Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methotrexate in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Composite immunogenicity and drug exposure response at 6 months. Planned start Apr 2019; status: withdrawn.
02
Drugs
methotrexate
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON48064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48064.